Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test

Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test

  • September 8, 2026

The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Biosciences. The flop leaves Novartis with one win and two failures from a rapid-fire run of key clinical readouts.

Leave A Comment

Fields (*) Mark are Required